Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study

Journal of Internal Medicine

Volumn 278, Issue 2, 2015, Pages 174-184

  Alan, M ^a   Grolimund, E ^a   Kutz, A ^a   Christ Crain, M ^b   Thomann, R ^c   Falconnier, C ^d   Hoess, C ^e   Henzen, C ^f   Zimmerli, W ^d   Mueller, B ^a   Schuetz, Philipp ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Burgerspital Solothurn   (Switzerland)

^d University Medical Clinic Liestal   (Switzerland)

^e Cantonal Hospital Thurgau Münsterlingen   (Switzerland)

^f LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

community acquired pneumonia; long term; mortality; outcomes; prognosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; PROADRENOMEDULLIN;

AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; CONTROLLED STUDY; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWITZERLAND; TIME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAUSE OF DEATH; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWITZERLAND; TIME FACTORS;

EID: 84923108198     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12341     Document Type: Article

References (39)

1. Menendez R, Torres A, Zalacain R et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960–5.
2. Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757–63.
3. Macfarlane J, Lewis SA, Macfarlane R, Holmes W. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: implications for developing management guidelines. Respir Med 1997; 91: 427–34.
4. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50.
5. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
6. SchuetzP, MarloweRJ, MuellerB. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med (in press).
7. GrolimundE, KutzA, MarloweRJet al. Long-term prognosis in COPD exacerbation: role of biomarkers, clinical variables and exacerbation type. COPD (in press).
8. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25: 1369–72.
9. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9: R816–24.
10. Christ-Crain M, Morgenthaler NG, Stolz D et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96.
11. Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Muller B. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007; 14: 345–51.
12. Huang DT, Angus DC, Kellum JA et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823–31.
13. Albrich WC, Ruegger K, Dusemund F et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013; 42: 1064–75.
14. Schuetz P, Wolbers M, Christ-Crain M et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14: R106.
15. Huang DT, Weissfeld LA, Kellum JA et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 48–58.e2.
16. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596–602.
17. Haeuptle J, Zaborsky R, Fiumefreddo R et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 55–60.
18. Schuetz P, Suter-Widmer I, Chaudri A et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011; 37: 384–92.
19. Lauridsen BK, Iversen K, Hunter I et al. ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. BMJ Open 2013; 3: e003288.
20. Muller B, Suess E, Schuetz P et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260: 568–76.
21. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084–91.
22. Vazquez M, Jockers K, Christ-Crain M, Zimmerli W, Muller B, Schuetz P. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study. Int J Cardiol 2012; 156: 16–23.
23. Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296–301.
24. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine 2008; 87: 329–34.
25. Yende S, Tuomanen EI, Wunderink R et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005; 172: 1440–6.
26. Brancati FL, Chow JW, Wagener MM, Vacarello SJ, Yu VL. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993; 342: 30–3.
27. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011; 37: 1439–46.
28. Schuetz P, Christ-Crain M, Wolbers M et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7: 102.
29. Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059–66.
30. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823–9.
31. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234–6.
32. Kruger S, Ewig S, Kunde J et al. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010; 65: 208–14.
33. El Solh A, Pineda L, Bouquin P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006; 6: 12.
34. Almirall J, Bolibar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335–42.
35. Menendez R, Martinez R, Reyes S et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987–92.
36. Seligman R, Meisner M, Lisboa TC et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10: R125.
37. Muller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10.
38. Albrich WC, Dusemund F, Ruegger K et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11: 112.
39. Albrich WC, Ruegger K, Dusemund F et al. Biomarker-enhanced triage in respiratory infections - a proof-of-concept feasibility trial. Eur Respir J 2013; 42: 1064–75.